



OPEN ACCESS

APPROVED BY
Frontiers Editorial Office,
Frontiers Media SA, Switzerland

*CORRESPONDENCE
Lijuan Chen,
chenlijuan125@163.com

[†]These authors have contributed equally
to this work and share first authorship

SPECIALTY SECTION
This article was submitted to
Cardiovascular and Smooth Muscle
Pharmacology,
a section of the journal
Frontiers in Pharmacology

RECEIVED 22 July 2022
ACCEPTED 17 August 2022
PUBLISHED 27 September 2022

CITATION
Liu J, Tang M, Li T, Su Z, Zhu Z, Dou C,
Liu Y, Pei H, Yang J, Ye H and Chen L
(2022), Corrigendum: Honokiol
ameliorates post-myocardial infarction
heart failure through Ucp3-mediated
reactive oxygen species inhibition.
Front. Pharmacol. 13:1000887.
doi: 10.3389/fphar.2022.1000887

COPYRIGHT
© 2022 Liu, Tang, Li, Su, Zhu, Dou, Liu,
Pei, Yang, Ye and Chen. This is an open-
access article distributed under the
terms of the [Creative Commons
Attribution License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use,
distribution or reproduction in other
forums is permitted, provided the
original author(s) and the copyright
owner(s) are credited and that the
original publication in this journal is
cited, in accordance with accepted
academic practice. No use, distribution
or reproduction is permitted which does
not comply with these terms.

Corrigendum: Honokiol ameliorates post-myocardial infarction heart failure through Ucp3-mediated reactive oxygen species inhibition

Jianyu Liu^{1†}, Minghai Tang^{1†}, Tao Li², Zhengying Su¹,
Zejiang Zhu¹, Caixia Dou¹, Yan Liu¹, Heying Pei¹,
Jianhong Yang¹, Haoyu Ye¹ and Lijuan Chen^{1*}

¹State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital of Sichuan University, Chengdu, China, ²West China-Washington Mitochondria and Metabolism Center, Department of Anesthesiology, Laboratory of Anesthesiology and Translational Neuroscience Center, West China Hospital of Sichuan University, Chengdu, China

KEYWORDS

heart failure, myocardial infarction, honokiol, reactive oxygen species, UCP3

A Corrigendum on Honokiol ameliorates post-myocardial infarction heart failure through Ucp3 mediated reactive oxygen species inhibition

by Liu J, Tang M, Li T, Su Z, Zhu Z, Dou C, Liu Y, Pei H, Yang J, Ye H and Chen L (2022). *Front. Pharmacol.* 13:811682. doi: 10.3389/fphar.2022.811682

In the published article, there was an error in the **Funding** statement. “This work was supported by National Key Programs of China during the 13th Five-Year Plan Period (2018ZX09711001-002-012) and 1.3.5 project for disciplines of excellence, West China Hospital, Sichuan University (ZY2017202).” The correct **Funding** statement appears below.

Funding

“This work was supported by National Key Programs of China during the 13th Five-Year Plan Period (2018ZX09711001-002-012) and 1.3.5 project for disciplines of excellence, West China Hospital, Sichuan University (ZYG20001).”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated

organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.